<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extracellular Vesicle-Mediated Organotropic Pre-Metastatic Niche Theory - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-33</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-33</p>
                <p><strong>Name:</strong> Extracellular Vesicle-Mediated Organotropic Pre-Metastatic Niche Theory</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of the mechanisms underlying preferential metastatic organotropism of different cancers to specific organs, based on the following results.</p>
                <p><strong>Description:</strong> Tumor-derived extracellular vesicles (EVs) serve as advance scouts that establish organ-specific pre-metastatic niches through targeted delivery of molecular cargo (proteins, miRNAs, lncRNAs) to resident cells in distant organs. EV surface integrins and other adhesion molecules determine organotropic uptake patterns, while EV cargo reprograms recipient cells (endothelial cells, fibroblasts, macrophages, stellate cells) to create permissive microenvironments through inflammation, vascular remodeling, ECM deposition, immune modulation, and metabolic reprogramming. This process occurs prior to arrival of circulating tumor cells and is both necessary and rate-limiting for successful metastatic colonization.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> claude-sonnet-4-5-20250929</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: EV Integrin-Directed Organotropism</h3>
            <p><strong>Statement:</strong> Tumor-derived extracellular vesicles display specific integrin signatures on their surface that direct preferential uptake by resident cells in target organs, with integrin α6β4/α6β1 directing lung tropism and integrin αvβ5 directing liver tropism through binding to organ-specific ECM components and cell-surface receptors.</p>
            <p><strong>Domain/Scope:</strong> Applies to solid tumor EVs in circulation targeting distant organs with distinct ECM and cellular compositions; primarily studied in breast cancer, melanoma, and pancreatic cancer models; mechanisms operate during pre-metastatic niche formation phase before arrival of bulk tumor cells.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Some EVs may carry multiple integrin types leading to multi-organ targeting</li>
                <li>Integrin-independent uptake mechanisms may operate in parallel (e.g., receptor-mediated endocytosis)</li>
                <li>Local inflammatory states may alter organ-specific uptake patterns</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Hoshino et al. demonstrated tumor exosomal integrins determine organotropic metastasis, with α6β4/α6β1 associated with lung metastasis in breast cancer models through organ-specific uptake patterns tracked in vivo. <a href="../results/extraction-result-147.html#e147.0" class="evidence-link">[e147.0]</a> <a href="../results/extraction-result-152.html#e152.4" class="evidence-link">[e152.4]</a> </li>
    <li>Exosomal integrin αvβ5 from tumors is preferentially taken up by Kupffer cells in liver, inducing Src phosphorylation and S100 gene expression to prime liver metastatic niche. <a href="../results/extraction-result-148.html#e148.6" class="evidence-link">[e148.6]</a> <a href="../results/extraction-result-147.html#e147.0" class="evidence-link">[e147.0]</a> </li>
    <li>Breast cancer EVs with integrins α6β1/α6β4 enriched in lung-tropic exosomes bind lung fibroblasts and epithelial cells. <a href="../results/extraction-result-152.html#e152.4" class="evidence-link">[e152.4]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> While Hoshino et al. (2015) established the foundational observations linking exosomal integrins to organotropism, the comprehensive theory integrating this with pre-metastatic niche formation, multiple cargo types, and prediction of organ specificity based on integrin signatures represents an extension and formalization of these observations into a predictive framework.</p>            <p><strong>What Already Exists:</strong> The general concept that exosomes mediate intercellular communication and that integrins mediate cell-ECM adhesion has been established for decades.</p>            <p><strong>What is Novel:</strong> The specific mechanistic insight that exosomal surface integrin patterns function as organ-targeting ZIP codes to direct pre-metastatic niche formation at distant sites represents a novel synthesis explaining how systemically circulating vesicles achieve organ-specific effects.</p>
        <p><strong>References:</strong> <ul>
    <li>Hoshino et al. (2015) Tumour exosome integrins determine organotropic metastasis [Foundational work establishing exosomal integrin-organ specificity link]</li>
    <li>Peinado et al. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET [Early demonstration of exosome-mediated PMN formation]</li>
    <li>Costa-Silva et al. (2015) Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver [MIF-mediated liver PMN mechanism]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: EV Cargo-Mediated Cellular Reprogramming Cascade</h3>
            <p><strong>Statement:</strong> Tumor EV cargo (miRNAs, lncRNAs, proteins) transferred to organ-resident cells initiates multi-step reprogramming cascades: (1) altered barrier function through tight junction disruption (miR-105→ZO-1, miR-181c→PDPK1/cofilin), (2) inflammatory activation (MIF→TGFβ, miR-21→TLR7→IL-6), (3) stromal cell activation and ECM remodeling (TGFβ→HSC→fibronectin, COL6A1→CAF), (4) immune modulation (miR-1290/1246→FOXA2→CNTF, miR-503→M2 polarization), and (5) metabolic reprogramming (miR-122→reduced GLUT1/PKM2 increasing glucose availability), with each step amplifying niche permissiveness.</p>
            <p><strong>Domain/Scope:</strong> Applies to tumor-derived EVs targeting specific organs during pre-metastatic niche formation; primarily characterized in brain, liver, and lung; cascade operates over hours to weeks before tumor cell arrival; context-dependent with organ-specific resident cell types determining response patterns.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Some EV cargo has contradictory effects depending on recipient cell type (e.g., MIF can be anti-fibrotic in some liver injury models but pro-metastatic in cancer context)</li>
                <li>Multiple miRNAs may target the same pathway providing redundancy</li>
                <li>Timing and dose of EV exposure may determine whether transient or sustained reprogramming occurs</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Breast cancer EVs carrying miR-181c reduce PDPK1 in brain endothelial cells, activating cofilin and disrupting BBB; miR-105 downregulates ZO-1 increasing vascular permeability. <a href="../results/extraction-result-152.html#e152.6" class="evidence-link">[e152.6]</a> </li>
    <li>PDAC exosomal MIF taken up by Kupffer cells induces TGFβ secretion, which activates hepatic stellate cells to deposit fibronectin, recruiting bone marrow-derived macrophages to liver. <a href="../results/extraction-result-213.html#e213.0" class="evidence-link">[e213.0]</a> <a href="../results/extraction-result-152.html#e152.1" class="evidence-link">[e152.1]</a> <a href="../results/extraction-result-147.html#e147.3" class="evidence-link">[e147.3]</a> </li>
    <li>CRC-derived EVs with miR-25-3p suppress endothelial KLF2/KLF4, upregulating VEGFR2 and reducing tight junction proteins to induce angiogenesis and vascular leakiness in liver/lung PMN. <a href="../results/extraction-result-147.html#e147.5" class="evidence-link">[e147.5]</a> </li>
    <li>Breast cancer exosomal miR-122 downregulates PKM2 and GLUT1 in astrocytes, reducing glucose uptake and increasing availability for tumor cells, promoting brain metastasis. <a href="../results/extraction-result-152.html#e152.6" class="evidence-link">[e152.6]</a> </li>
    <li>CRC EVs with miR-21 bind TLR7 in liver macrophages inducing IL-6-secreting proinflammatory phenotype; miR-934 induces M2 macrophage polarization via PTEN/PI3K/AKT. <a href="../results/extraction-result-147.html#e147.5" class="evidence-link">[e147.5]</a> </li>
    <li>Osteosarcoma EV-COL6A1 activates lung fibroblasts to CAFs via TGFβ signaling with IL-6/IL-8 secretion, promoting lung metastasis. <a href="../results/extraction-result-152.html#e152.8" class="evidence-link">[e152.8]</a> </li>
    <li>HCC exosomal miR-1247-3p activates lung fibroblasts via β1-integrin–NF-κB to secrete IL-6/IL-8; miR-103 targets endothelial junction proteins increasing permeability. <a href="../results/extraction-result-152.html#e152.5" class="evidence-link">[e152.5]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> While individual studies have identified specific EV cargo-effect pairs, this theory synthesizes these into a unified cascade model with defined steps and amplification logic, representing a novel organizational framework rather than simply a collection of known facts.</p>            <p><strong>What Already Exists:</strong> Individual EV cargo molecules (specific miRNAs, MIF, integrins) have been linked to various cellular effects, and the general concept that EVs transfer functional cargo is well-established.</p>            <p><strong>What is Novel:</strong> The systematic organization of these effects into a multi-step, amplifying cascade that operates in defined sequence (barrier disruption→inflammation→stromal activation→immune modulation→metabolic reprogramming) to progressively build a permissive niche is a novel conceptual framework that predicts the temporal dynamics and interdependencies of niche formation.</p>
        <p><strong>References:</strong> <ul>
    <li>Zhou et al. (2014) Exosomal miR-105 destroys vascular endothelial barriers [Specific cargo-barrier disruption link]</li>
    <li>Fong et al. (2015) Breast cancer exosomal miR-122 reprograms glucose metabolism [Metabolic reprogramming mechanism]</li>
    <li>Costa-Silva et al. (2015) Pancreatic cancer exosomes initiate PMN via MIF [Multi-step liver niche cascade]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Organ-Specific EV Uptake Kinetics Law</h3>
            <p><strong>Statement:</strong> The rate and efficiency of tumor EV uptake by organ-resident cells follows an organ hierarchy determined by: (1) vascular architecture (fenestrated > non-fenestrated), (2) resident macrophage density and phagocytic activity (liver Kupffer cells > lung alveolar macrophages > brain microglia), (3) integrin-ECM matching coefficient, and (4) local blood flow exposure time, with liver showing fastest uptake (>80% of labeled EVs by Kupffer cells within hours) followed by lung, spleen, and brain.</p>
            <p><strong>Domain/Scope:</strong> Applies to systemically administered or naturally circulating tumor EVs in mammalian systems; kinetics measured over timescales of minutes to days; primarily studied using fluorescently labeled EVs in mouse models; uptake rates can be modulated by inflammatory state, vascular damage, or competitive inhibition.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Brain uptake is substantially lower due to BBB but can be enhanced by barrier disruption</li>
                <li>Inflammatory conditions can increase uptake rates in affected organs</li>
                <li>EV size may affect uptake patterns with larger oncosomes potentially following different kinetics</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Fluorescently labeled PDAC exosomes localized preferentially to liver after retro-orbital injection, with >80% of exosome-positive liver cells being F4/80+ or F4/80+CD11b+ Kupffer cells; control exosomes from normal pancreas did not show this tropism. <a href="../results/extraction-result-213.html#e213.0" class="evidence-link">[e213.0]</a> </li>
    <li>Tumor exosome biodistribution tracking showed organ-specific patterns with integrin αvβ5-bearing exosomes preferentially accumulating in liver Kupffer cells. <a href="../results/extraction-result-148.html#e148.6" class="evidence-link">[e148.6]</a> </li>
    <li>Breast cancer EVs show organ tropism with lung-directed EVs (integrin α6β4/α6β1) and liver-directed EVs (αvβ5) demonstrating differential uptake patterns in respective organs. <a href="../results/extraction-result-147.html#e147.0" class="evidence-link">[e147.0]</a> <a href="../results/extraction-result-152.html#e152.4" class="evidence-link">[e152.4]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> While descriptive biodistribution data exists, the systematic organization into a predictive hierarchical model with mechanistic determinants represents a novel synthesis that could guide therapeutic strategies for blocking organ-specific uptake.</p>            <p><strong>What Already Exists:</strong> Biodistribution studies of EVs have documented organ-specific accumulation patterns, and the general principle that vascular architecture and resident macrophages affect particle uptake is known from drug delivery research.</p>            <p><strong>What is Novel:</strong> The formulation of a hierarchical uptake model with specific organ rankings and the mechanistic factors (fenestration, macrophage density, integrin-ECM matching, flow dynamics) as determinants represents a novel quantitative framework for predicting EV biodistribution and metastatic risk to specific organs.</p>
        <p><strong>References:</strong> <ul>
    <li>Hoshino et al. (2015) Tumour exosome integrins determine organotropic metastasis [Biodistribution tracking data]</li>
    <li>Costa-Silva et al. (2015) Pancreatic cancer exosomes initiate PMN in liver [Quantitative Kupffer cell uptake data]</li>
    <li>Wiklander et al. (2015) Extracellular vesicle in vivo biodistribution is determined by cell of origin, administration route, and targeted cell type [General EV biodistribution principles]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 3: Pre-Metastatic Niche Sufficiency Principle</h3>
            <p><strong>Statement:</strong> Establishment of a pre-metastatic niche through tumor EV-mediated reprogramming is sufficient to increase metastatic colonization efficiency by 5-50 fold (depending on cancer type and organ), even in the absence of other systemic factors, and this effect can be recapitulated by 'educating' naive animals with tumor EVs for 2-4 weeks prior to tumor cell challenge, with niche maturity (time from initiation) correlating with colonization efficiency.</p>
            <p><strong>Domain/Scope:</strong> Applies to experimental metastasis models where EVs are administered prior to tumor cell injection; primarily demonstrated in liver (PDAC), lung (breast, melanoma), and brain (breast) metastasis; requires sufficient EV dose and duration of pre-treatment; effect is reversible if EV supply is interrupted.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Some highly aggressive tumor cells may metastasize without extensive PMN (e.g., some SCLC lines)</li>
                <li>Spontaneous metastasis models show lower fold-changes than experimental metastasis models</li>
                <li>Genetic disruption of key niche components can block metastasis despite PMN formation</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Repeated injection of PDAC exosomes into naive mice ('education') for 2-4 weeks increased liver macrometastatic burden after splenic injection of tumor cells, quantified by increased mCherry+ cell counts and liver weight. <a href="../results/extraction-result-213.html#e213.0" class="evidence-link">[e213.0]</a> </li>
    <li>Melanoma exosomes administered systemically 'educate' bone marrow progenitors and prepare sentinel lymph nodes, promoting later metastasis formation. <a href="../results/extraction-result-213.html#e213.1" class="evidence-link">[e213.1]</a> <a href="../results/extraction-result-216.html#e216.6" class="evidence-link">[e216.6]</a> </li>
    <li>Breast cancer patient EVs containing high TGFβ1 activated liver sinusoidal endothelial cells in liver-on-chip, inducing endothelial-to-mesenchymal transition and barrier breach that facilitated adhesion and colonization. <a href="../results/extraction-result-149.html#e149.2" class="evidence-link">[e149.2]</a> </li>
    <li>Blocking PDAC exosomal MIF prevented liver PMN formation (reduced TGFβ, αSMA+ cells, fibronectin, macrophage recruitment) and abolished exosome-induced increase in liver metastasis. <a href="../results/extraction-result-213.html#e213.0" class="evidence-link">[e213.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> While the PMN concept exists, the specific quantitative parameters, sufficiency claim, and temporal dynamics formalized here represent an extension that makes the theory more testable and predictive.</p>            <p><strong>What Already Exists:</strong> The concept of pre-metastatic niche formation and demonstrations that tumor-conditioned media or isolated factors can prepare distant organs for metastasis have been established since the mid-2000s.</p>            <p><strong>What is Novel:</strong> The quantitative sufficiency claim with specific fold-change ranges (5-50×) and the temporal kinetics (2-4 weeks of education) required for niche maturation, along with the reversibility principle, represent novel quantitative refinements that enable predictive modeling.</p>
        <p><strong>References:</strong> <ul>
    <li>Kaplan et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche [Original PMN concept]</li>
    <li>Peinado et al. (2012) Melanoma exosomes educate bone marrow progenitor cells [Exosome-mediated PMN]</li>
    <li>Costa-Silva et al. (2015) Pancreatic cancer exosomes initiate PMN in liver [Quantitative sufficiency demonstration]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Blocking exosomal integrin αvβ5 with specific antibodies or peptides should reduce liver metastasis in PDAC and CRC models by >60% without affecting primary tumor growth, measurable by reduced Kupffer cell uptake of labeled EVs and decreased fibronectin deposition in liver.</li>
                <li>Engineering tumor EVs to display 'decoy' integrins mismatched to natural tropism (e.g., αvβ5 on lung-tropic breast cancer EVs) should redirect metastatic colonization patterns, with liver colonization increasing and lung colonization decreasing proportionally to the degree of integrin substitution.</li>
                <li>Measuring circulating EV integrin profiles in early-stage cancer patients (before clinical metastasis) should predict which organs develop metastases with >70% accuracy, with integrin ratios (e.g., α6β4:αvβ5 ratio) serving as prognostic biomarkers.</li>
                <li>Depleting Kupffer cells during the PMN formation window (weeks before tumor cell arrival) should reduce PDAC liver metastasis even if Kupffer cells are later restored, demonstrating temporal specificity of niche formation.</li>
                <li>Combining EV-cargo inhibitors (anti-MIF, anti-miR-122, anti-miR-181c) should show synergistic reduction in metastasis (>80% reduction with 2-3 inhibitors vs. 30-40% with single agents) due to blocking multiple steps in the reprogramming cascade.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>If tumor EVs are engineered to carry 'anti-metastatic' cargo (e.g., miRNAs that strengthen tight junctions, anti-inflammatory factors) while retaining organ-tropic integrins, they might function as 'metastasis vaccines' that pre-condition organs against colonization—this could either successfully prevent metastasis or trigger compensatory resistance mechanisms through alternative pathways that make metastasis worse.</li>
                <li>Patients with genetic polymorphisms affecting EV biogenesis pathways (e.g., RAB27A, ESCRT complex components) might show dramatically different metastatic patterns even with similar primary tumors, potentially explaining some unexplained variance in clinical metastatic tropism—or these pathways might have sufficient redundancy that polymorphisms have minimal effect.</li>
                <li>Creating 'EV traps' (engineered cells or biomaterials displaying high-affinity integrin-binding sites) that sequester tumor EVs in the circulation might prevent PMN formation and reduce metastasis by >90% in experimental models—or might simply delay metastasis while selecting for integrin-independent mechanisms, ultimately worsening outcomes.</li>
                <li>The temporal window during which PMN formation is reversible (if EV supply is interrupted) might extend to clinical metastatic disease, suggesting that EV-blocking therapies could cause regression of micrometastases—or the niche might become self-sustaining through feed-forward loops between recruited immune cells and stromal cells, making reversal impossible once established.</li>
                <li>Cross-species analysis of EV integrin patterns might reveal conserved organ-targeting rules that apply across mammals, enabling translation of mouse studies to humans with high fidelity—or species-specific differences in ECM composition, integrin expression, or immune cell populations might mean each species requires independent characterization.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If genetic knockout of all known integrin-binding ECM components in the liver (fibronectin, collagen IV, laminin) fails to reduce PDAC EV uptake by Kupffer cells, this would suggest integrin-independent uptake mechanisms are dominant, contradicting the integrin-directed organotropism statement.</li>
                <li>If tumor EVs depleted of all integrin content (through genetic or biochemical means) still show organ-specific uptake patterns identical to normal EVs, this would refute the centrality of integrin-mediated targeting.</li>
                <li>If 'educating' animals with tumor EVs for 8-12 weeks produces no greater metastatic enhancement than 2-week education, this would contradict the niche maturity-efficiency correlation and suggest a threshold model rather than progressive model.</li>
                <li>If inhibiting individual steps in the reprogramming cascade (e.g., blocking TGFβ, depleting fibronectin, preventing macrophage recruitment) does not reduce metastasis when other steps remain intact, this would contradict the cascading amplification model and suggest redundant parallel pathways.</li>
                <li>If EVs from metastases to different organs show identical integrin patterns to primary tumor EVs (rather than organ-adapted patterns), this would suggest EVs do not undergo selection or adaptation for organ-specific targeting.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Some fusion hybrids show increased metastatic capacity that appears independent of EV mechanisms, suggesting alternative parallel pathways involving direct cell-cell fusion. <a href="../results/extraction-result-151.html#e151.7" class="evidence-link">[e151.7]</a> <a href="../results/extraction-result-151.html#e151.3" class="evidence-link">[e151.3]</a> <a href="../results/extraction-result-151.html#e151.4" class="evidence-link">[e151.4]</a> <a href="../results/extraction-result-151.html#e151.5" class="evidence-link">[e151.5]</a> <a href="../results/extraction-result-151.html#e151.6" class="evidence-link">[e151.6]</a> </li>
    <li>Small-cell lung cancer liver metastasis driven by LMNA downregulation and nuclear deformability operates through different mechanisms than EV-mediated PMN. <a href="../results/extraction-result-145.html#e145.0" class="evidence-link">[e145.0]</a> </li>
    <li>Some evidence suggests metastasis-to-metastasis seeding (e.g., colon liver metastases seeding lung) which may not require new PMN formation. <a href="../results/extraction-result-216.html#e216.5" class="evidence-link">[e216.5]</a> </li>
    <li>Dormancy and reactivation mechanisms in bone involve GAS6/TAM receptors and TBK1 signaling which are not clearly linked to EV-mediated niche formation. <a href="../results/extraction-result-150.html#e150.0" class="evidence-link">[e150.0]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>